The pharmaceuticals industry is one of the strategic industries in Egypt. 
There is a high domestic production capacity, but the industry remains heavily dependent on imported raw materials. 
Prices have been strictly controlled and have not been allowed to rise to keep pace with inflation or the recent sharp decrease in the value of the Egyptian Pound. 
As a result, pharmaceutical companies have been subject to significant downward pressure on their net revenues, and the industry has become less competitive in the global market and less attractive to investors.

Local pharmaceutical companies face further difficulties due to exposure to new rules on protection of intellectual property rights (TRIPS), requiring Egypt to provide full patent protection by the year 2005.

With bottom lines shrinking, global and local competition intensifying, and the peculiarities of the Egyptian market continuing to include extensive governmental regulations and immature distribution channels, the value of enhanced financial control and improved operations may be critical to business success.

KPMG member firms provide a broad range of risk advisory, tax, financial and business advisory services. This strength in depth allows us to review many business problems in today’s rapidly changing pharmaceuticals industry, and to help you to improve your operational efficiency.